Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Calypte Biomedical Corporation (CALY) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Thayres who wrote (276)	6/1/1998 10:50:00 AM
From: Winston Kim	Read Replies (1) \| Respond to of 381

This is huge and volume picking up...should break..52 week high...come on CALY!!!!

To: Michael Thayres who wrote (276)	6/2/1998 8:09:00 AM
From: JanyBlueEyes	Respond to of 381

BERKELEY, Calif.--(BW HealthWire)--June 1, 1998--In response to a news item that ran across the Associated Press Wire on June 1 at 16:25 EDT, Calypte Biomedical Corporation issued the following statement as clarification: "The FDA official quoted in the AP story was misleading in his characterization of the accuracy of the urine Western blot. The two individuals identified as having been 'missed' by the urine test were, in fact, undergoing anti-retroviral therapy for AIDS which has the effect of lowering the level of viral load and often the associated antibodies. The urine-only test system is intended to be used on individuals who do not know their HIV status. In addition, the story did not point out that, in a separate study of high-risk individuals, three samples that tested positive using the urine system had tested negative using a blood screening test. As further evidence of the urine test's importance as a public health tool, the journal Nature Medicine published an article in November 1997 which cited independent scientists who were able to use the urine test to isolate or identify HIV in two individuals that tested negative by the blood antibody test." See Message 2674013 CONTACT: Healy Communication John Healy/Jason Sherman 312/440-3900